Maintenance, man: Lilly’s phase III weight trial hits goals
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small molecule GLP-1 receptor agonist. Indianapolis-based Lilly said that at one year orforglipron met the primary and all […]
Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow – statnews.com
Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow statnews.com Opinion | How to cut the velvet rope to GLP-1s The Washington Post Obesity recognition ‘going in right direction’ amid GLP-1 revolution, but obstacles remain thehill.com Covering the High Cost of Weight Loss Drugs National Conference of State Legislatures (NCSL) Study finds 40% of GLP-1 prescriptions […]
Eli Lilly’s Experimental Pill Could Help You Ditch GLP-1 Obesity Shots, Trial Finds
People who switched from semaglutide or tirzepatide to orforglipron largely maintained their weight loss.
Orforglipron Helps Maintain Weight Loss After Injectables
Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people maintain weight loss after switching from an injectable. Medscape Medical News
Eli Lilly is eyeing an off-ramp for patients to switch from weight loss injections to pills
Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to take and will be cheaper
Can you get addicted to a GLP-1?
Model Brooks Nader calls these drugs a “crutch.”
Neovascular Age-Related Macular Degeneration and GLP-1 RAs—Reply
In Reply We read the letters with great interest commenting on our recent article. We agree that surveillance bias is a concern in observational studies using administrative data. To mitigate this, we implemented several methodological approaches. First, we used duration of diabetes as a covariate in propensity score matching, which serves as a proxy for […]
Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role
NEW YORK–(BUSINESS WIRE)–The 43rd Barometer from Sermo, a fast, frictionless HCP social engagement platform and leader in healthcare insights, shows that pharma-led direct-to-patient (DTP) GLP-1 prescribing programs are transforming treatment access pathways. Yet findings from 953 surveyed GLP-1 prescribers reveal sharp divisions over how involved pharma should be in clinical evaluation and prescribing. DTP Models […]
More GLP-1s aim to enter US market
Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker. CagriSema is a weekly injection of semaglutide, a GLP-1, and cagrilintide, a long-acting amylin analogue. If approved, the drug would be the first injectable GLP-1 and amylin analogue combination […]
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
Novo Nordisk NVO is a leading player in the obesity market, driven by its blockbuster GLP-1 therapy Wegovy (semaglutide). However, despite being a core growth driver, Wegovy’s sales momentum has slowed in recent quarters. The deceleration is primarily attributed to intensifying competition in the GLP-1 space, most notably from its arch-rival Eli Lilly LLY, as well […]